Downregulation of LEMD1-AS1 and Its Influences on the Diagnosis, Prognosis, and Immune Infiltrates of Epithelial Ovarian Cancer

Table 1

Association between LEMD1-AS1 expression and clinicopathological characteristics of EOC.

Characteristic	Low expression of LEMD1-AS1	High expression of LEMD1-AS1
	189	190
FIGO stage,			0.151
Stage I	0 (0%)	1 (0.3%)
Stage II	7 (1.9%)	16 (4.3%)
Stage III	152 (40.4%)	143 (38%)
Stage IV	29 (7.7%)	28 (7.4%)
Primary therapy outcome,			0.109
PD	18 (5.8%)	9 (2.9%)
SD	11 (3.6%)	11 (3.6%)
PR	26 (8.4%)	17 (5.5%)
CR	100 (32.5%)	116 (37.7%)
Race,			0.501
Asian	4 (1.1%)	8 (2.2%)
Black or African American	13 (3.6%)	12 (3.3%)
White	165 (45.2%)	163 (44.7%)
Age,			0.646
≤60	101 (26.6%)	107 (28.2%)
>60	88 (23.2%)	83 (21.9%)
Histologic grade,			0.874
G1	0 (0%)	1 (0.3%)
G2	23 (6.2%)	22 (6%)
G3	163 (44.2%)	159 (43.1%)
G4	0 (0%)	1 (0.3%)
Age, median (IQR)	60 (52, 70)	58 (50.25, 66.75)	0.161